Faecal steroid loss in healthy subjects during short-term treatment with ursodeoxycholic acid.
Faecal steroid loss in healthy subjects during short-term treatment with ursodeoxycholic acid has been investigated. The data shows conclusively that lithocholic acid, a known co-mutagen and co-carcinogen is the major bacterial metabolite of ursodeoxycholic acid in the human intestine. Although ursodeoxycholic acid is now the drug of choice for dissolution of cholesterol gallstones, elevation of intestinal lithocholic acid may have long-term repercussions since it has been demonstrated that a high faecal lithocholic acid: deoxycholic acid ratio shows a positive correlation with the incidence of colorectal cancer.
D001647:Bile Acids and Salts / Q000032:analysis / Q000378:metabolism; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D005243:Feces / Q000032:analysis*; D005998:Glycine / Q000378:metabolism; D006801:Humans; D008297:Male; D013261:Sterols / Q000378:metabolism*; D013654:Taurine / Q000378:metabolism; D014580:Ursodeoxycholic Acid / Q000378:metabolism / Q000494:pharmacology*
D001647:Bile Acids and Salts; D013261:Sterols; D003840:Deoxycholic Acid; D013654:Taurine; D014580:Ursodeoxycholic Acid; D005998:Glycine